NEUROCRINE BIOSCIENCES INC Form 4/A March 17, 2003

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4/A

FORM 4/A

longer subject to Section 16.

o Check this box if no

Form 4 or Form 5

See Instruction 1(b).

(Print or Type Responses)

obligations

may continue.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response 0.5

 Name and Address of Reporting Person* Mollica, Joe 	2. Issuer Name and Tic Symbol Neurocrine Biosciences	C	6. Relationship of Reporting Person(s) to issuer (Check all applicable) x Director o 10% Owner o Officer (give title below) o Other (specify below)							
(Last) (First) (Middle) Box 1182	3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary)	4. Statement for Month/Year 3/14/03								
(Street) Princeton, NJ 08542		5. If Amendment, Date of Original (Month/Year) 03/14/03	 7. Individual or Joint/Group Filing (Check Applicable Line) x Form filed by One Reporting Person o Form filed by More than One Reporting Person 							
(City) (State) (Zip)										

TABLE I NON-DERIVATIVE SECURITIES ACQUIRED, DISPOSED OF, OR BENEFICIALLY OWNED

1. Title of Security (Instr. 3)	2. Transaction Date (Month/ Day/ Year)	3. Transaction Code (Instr. 8)			4. Securitie Disposed o (Instr. 3, 4	f (D)	(A	.) or	5. Amount of Securities Beneficially Owned at End of Month (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Code	,	v	Amount	(A) or (D)		Price				
Common Stock	3/13/03	S			45,000	D		\$41.82		D		
Common Stock	3/13/03	М			10,000	А		\$5.25		D		
Common Stock	3/13/03	М			10,000	А		\$8.3125		D		
Common Stock	3/13/03	М			10,000	А		\$10.25		D		
Common Stock	3/13/03	М			15,000	A		\$7.75		D	$\frac{1}{1}$	

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4/A

Reminder: Report on separate line for each class of securities beneficially owned directly or indirectly. *If the form is filed by more than one reporting person, *see* instruction

4(b)(v).

Potential persons who are to respond to the collection of
information contained in this form are not required to respond
unless the form displays a currently valid OMG control number.(Over)(3-99)

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4/A

of 2. Conversion or Exercise Price of Derivative Security	4. Tran Code (Instr. 8		of De Secur Acqu	ired (A) sposed) . 3, 4,	6. Date Exercisab and Expir Date (Month/D	ation	7. Title Amour Underl Securit (Instr. 3	nt of ying	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned at End of Month (Instr. 4)	10. Ownership Form of Derivative Security Direct (D) or Indirect (I) (Instr. 4)	1 of Ind Be Ov (Ir		
			Code	V	(A)	(D)	Date Exercis- able	Expira- tion Date	Title	Amount or Number of Shares				
	\$5.25	3/13/03	М			D				10,000	\$5.25	0	D	
	\$8.3125	3/13/03	М			D				10,000	\$8.3125	0	D	
	\$10.25	3/13/03	М			D				10,000	\$10.25	0	D	
	\$7.75	3/13/03	М			D				15,000	\$7.75	0	D	
┢┼┼	+	<u> </u>	└┨───┨	╶┼─┤			+		$\left \right $					\vdash

 Table II
 Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Explanation of Responses:

FORM 4/A

(continued)

3/14/03

Margaret E. Valeur-Jensen

Date

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMG Number.

Page 2